Tien Liang BioTech Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Tien Liang BioTech has been growing earnings at an average annual rate of 55%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 1.7% per year. Tien Liang BioTech's return on equity is 2.1%, and it has net margins of 2.3%.
Belangrijke informatie
55.0%
Groei van de winst
55.0%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 18.5% |
| Inkomstengroei | 1.7% |
| Rendement op eigen vermogen | 2.1% |
| Nettomarge | 2.3% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Tien Liang BioTech geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 426 | 10 | 251 | 1 |
| 31 Mar 24 | 453 | 19 | 261 | 1 |
| 31 Dec 23 | 460 | 18 | 266 | 1 |
| 30 Sep 23 | 477 | 26 | 268 | 1 |
| 30 Jun 23 | 490 | 36 | 272 | 1 |
| 31 Mar 23 | 504 | 41 | 276 | 1 |
| 31 Dec 22 | 529 | 59 | 277 | 1 |
| 30 Sep 22 | 558 | 70 | 280 | 1 |
| 30 Jun 22 | 595 | 82 | 285 | 1 |
| 31 Mar 22 | 608 | 83 | 287 | 1 |
| 31 Dec 21 | 571 | 47 | 294 | 1 |
| 30 Sep 21 | 518 | 7 | 298 | 1 |
| 30 Jun 21 | 455 | -32 | 300 | 1 |
| 31 Mar 21 | 423 | -62 | 305 | 1 |
| 31 Dec 20 | 431 | -52 | 301 | 1 |
| 30 Sep 20 | 452 | -26 | 291 | 1 |
| 30 Jun 20 | 450 | -33 | 290 | 1 |
| 31 Mar 20 | 446 | -31 | 292 | 1 |
| 31 Dec 19 | 436 | -47 | 301 | 1 |
| 30 Sep 19 | 452 | -90 | 312 | 1 |
| 30 Jun 19 | 478 | -101 | 323 | 2 |
| 31 Mar 19 | 520 | -103 | 338 | 3 |
| 31 Dec 18 | 534 | -94 | 344 | 3 |
| 30 Sep 18 | 518 | -66 | 362 | 3 |
| 30 Jun 18 | 494 | 37 | 389 | 2 |
| 31 Mar 18 | 472 | -196 | 412 | 2 |
| 31 Dec 17 | 515 | -203 | 451 | 2 |
| 30 Sep 17 | 563 | -230 | 473 | 1 |
| 30 Jun 17 | 641 | -317 | 488 | 1 |
| 31 Mar 17 | 716 | -75 | 489 | 2 |
| 31 Dec 16 | 756 | -53 | 481 | 2 |
| 30 Sep 16 | 765 | -27 | 474 | 2 |
| 30 Jun 16 | 788 | -1 | 460 | 3 |
| 31 Mar 16 | 813 | 24 | 462 | 2 |
| 31 Dec 15 | 841 | 49 | 460 | 2 |
| 30 Sep 15 | 863 | 67 | 469 | -8 |
| 30 Jun 15 | 886 | 76 | 461 | -5 |
| 31 Mar 15 | 875 | 74 | 444 | -2 |
| 31 Dec 14 | 844 | 61 | 428 | 1 |
| 30 Sep 14 | 826 | 52 | 405 | 13 |
| 30 Jun 14 | 794 | 45 | 394 | 14 |
| 31 Mar 14 | 855 | 53 | 420 | 14 |
| 31 Dec 13 | 918 | 49 | 453 | 15 |
Kwaliteitswinsten: 4127 has high quality earnings.
Groeiende winstmarge: 4127's current net profit margins (2.3%) are lower than last year (7.4%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 4127 has become profitable over the past 5 years, growing earnings by 55% per year.
Versnelling van de groei: 4127's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 4127 had negative earnings growth (-73%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.6%).
Rendement op eigen vermogen
Hoge ROE: 4127's Return on Equity (2.1%) is considered low.